2023
US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021
Elmarasi M, Fuehrlein B. US Medicaid program: An analysis of the spending and utilization patterns for antidepressants from 2017 to 2021. Exploratory Research In Clinical And Social Pharmacy 2023, 13: 100392. PMID: 38149102, PMCID: PMC10750172, DOI: 10.1016/j.rcsop.2023.100392.Peer-Reviewed Original ResearchMajor depressive disorderMonoamine oxidase inhibitorsTricyclic antidepressantsDepressive disorderCommon mental health concernsStudy periodClasses of antidepressantsMedicaid programUS Medicaid programMental health conditionsSerious mental health conditionsPublic health systemMental health concernsAntidepressant prescriptionsSingle antidepressantTreatment patternsAntidepressant usagePrescription dataMedicaid dataUS adultsAntidepressantsHealth complicationsLifetime diagnosisOxidase inhibitorsHealth system
2022
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki S, Bjork J, Blow F, Brenner L, Chen P, Desai S, Dieperink E, Fears S, Fuller M, Goodman C, Graham D, Haas G, Hamner M, Helstrom A, Hurley R, Icardi M, Jurjus G, Kilbourne A, Kreyenbuhl J, Lache D, Lieske S, Lynch J, Meyer L, Montalvo C, Muralidhar S, Ostacher M, Paschall G, Pfeiffer P, Prieto S, Przygodzki R, Ranganathan M, Rodriguez-Suarez M, Roggenkamp H, Schichman S, Schneeweis J, Simonetti J, Steinhauer S, Suppes T, Umbert M, Vassy J, Voora D, Wiechers I, Wood A. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder. JAMA 2022, 328: 151-161. PMID: 35819423, PMCID: PMC9277497, DOI: 10.1001/jama.2022.9805.Peer-Reviewed Original ResearchConceptsMajor depressive disorderPatient Health Questionnaire-9Usual care groupUsual carePharmacogenomic testingDrug-gene interactionsRemission rateMedication selectionCare groupDepressive disorderVeterans Affairs Medical CenterActive substance use disorderCo-primary outcomesPrescription of medicationsBetter clinical outcomesProportion of prescriptionsRemission of symptomsSubstance use disordersEligible patientsWeek 24Effective antidepressantSingle antidepressantClinical outcomesInitial treatmentQuestionnaire-9
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply